IART Integra Lifesciences Holdings Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IART

Price (delayed)

$29.38

Market cap

$2.3B

P/E Ratio

34.56

Dividend/share

N/A

EPS

$0.85

Enterprise value

$3.7B

Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra ...

Highlights
The stock's price to earnings (P/E) is 27% less than its 5-year quarterly average of 47.1
IART's quick ratio is up by 24% from the previous quarter but it is down by 17% YoY
Integra Lifesciences Holdings's net income has plunged by 62% YoY and by 33% from the previous quarter
IART's EPS has dropped by 61% year-on-year and by 31% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.integralife.com
Peers: SYK TFX XRAY CNMD

Key stats

What are the main financial stats of IART
Market
Shares outstanding
78.22M
Market cap
$2.3B
Enterprise value
$3.7B
Valuations
Price to earnings (P/E)
34.56
Price to book (P/B)
1.45
Price to sales (P/S)
1.53
EV/EBIT
27.96
EV/EBITDA
14.35
EV/Sales
2.4
Earnings
Revenue
$1.54B
EBIT
$132.45M
EBITDA
$258.15M
Free cash flow
$73.09M
Per share
EPS
$0.85
Free cash flow per share
$0.91
Book value per share
$20.31
Revenue per share
$19.25
TBVPS
$20.71
Balance sheet
Total assets
$3.78B
Total liabilities
$2.19B
Debt
$1.68B
Equity
$1.59B
Working capital
$751.06M
Liquidity
Debt to equity
1.06
Current ratio
3.45
Quick ratio
1.85
Net debt/EBITDA
5.44
Margins
EBITDA margin
16.7%
Gross margin
57.4%
Net margin
4.4%
Operating margin
7.2%
Efficiency
Return on assets
1.8%
Return on equity
4.2%
Return on invested capital
5%
Return on capital employed
3.8%
Return on sales
8.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IART stock price

How has the Integra Lifesciences Holdings stock price performed over time
Intraday
0%
1 week
-8.02%
1 month
-12.97%
1 year
-50.02%
YTD
-32.54%
QTD
-17.12%

Financial performance

How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.54B
Gross profit
$884.74M
Operating income
$111.53M
Net income
$67.74M
Gross margin
57.4%
Net margin
4.4%
Integra Lifesciences Holdings's net income has plunged by 62% YoY and by 33% from the previous quarter
The net margin has dropped by 62% year-on-year and by 32% since the previous quarter
IART's operating margin has dropped by 53% year-on-year and by 23% since the previous quarter
The operating income has dropped by 53% year-on-year and by 22% since the previous quarter

Growth

What is Integra Lifesciences Holdings's growth rate over time

Valuation

What is Integra Lifesciences Holdings stock price valuation
IART P/E details
P/E
34.56
P/B
1.45
P/S
1.53
EV/EBIT
27.96
EV/EBITDA
14.35
EV/Sales
2.4
IART's EPS has dropped by 61% year-on-year and by 31% since the previous quarter
The stock's price to earnings (P/E) is 27% less than its 5-year quarterly average of 47.1
The P/B is 52% lower than the 5-year quarterly average of 3.0 and 34% lower than the last 4 quarters average of 2.2
The equity has declined by 12% year-on-year
The price to sales (P/S) is 51% less than the 5-year quarterly average of 3.1 and 33% less than the last 4 quarters average of 2.3

Efficiency

How efficient is Integra Lifesciences Holdings business performance
IART's ROA has shrunk by 63% YoY and by 33% QoQ
Integra Lifesciences Holdings's return on equity has shrunk by 60% YoY and by 30% QoQ
IART's return on invested capital has dropped by 51% year-on-year and by 22% since the previous quarter
IART's return on sales is down by 49% year-on-year and by 20% since the previous quarter

Dividends

What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IART.

Financial health

How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 72% higher than its total liabilities
IART's quick ratio is up by 24% from the previous quarter but it is down by 17% YoY
The current ratio has grown by 19% since the previous quarter but it has declined by 4.7% year-on-year
The debt is 6% greater than the equity
Integra Lifesciences Holdings's debt to equity has increased by 18% YoY
The equity has declined by 12% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.